MICROCOAT BIOTECHNOLOGIE GMBH

Their core work

Microcoat Biotechnologie GmbH is a German biotechnology SME specializing in the development and production of coated microparticles, liposome-based reagents, and surface-functionalized components used in diagnostic assays and biosensors. Their core competency lies in the precision chemistry of biological surfaces — enabling technologies such as liposome lysis assays, complement-pathway immunoassays, and multiplex biosensor platforms that detect inflammatory markers. In their EU projects, they act as a reagent and assay component supplier, bringing proprietary microcoating know-how to collaborative diagnostic platforms. Their work bridges basic immunology (complement system, inflammation biomarkers) and applied point-of-care device development.

What they specialise in

How they've shifted over time

With only two projects and no keywords recorded for the earlier iLCA project, the evolution picture is partial but directionally clear. Their first project (iLCA, 2019–2021) focused on live cell analysis for general disease management — a broader, device-level application. By their second project (SciFiMed, 2021–2025), the focus sharpened considerably onto inflammation biology, complement system diagnostics, and multiplex quantitative biosensors — a more specialized, biomarker-driven niche. The trend points toward increasing depth in immunological point-of-care diagnostics rather than breadth across disease areas.

Microcoat is moving toward highly specialized complement-system diagnostics and multiplex inflammation biomarker detection — a niche with strong commercial potential in personalized medicine and chronic disease monitoring.

How they like to work

Microcoat has never coordinated an H2020 project, participating exclusively as a specialist partner in both projects. This is consistent with a small SME that brings a specific proprietary capability — microcoated reagents or assay components — to consortia led by larger academic or clinical partners. With 9 unique partners across just 2 projects, they engage in moderately sized consortia rather than bilateral arrangements, suggesting they are comfortable operating within multi-stakeholder research teams.

Microcoat has built a network of 9 unique consortium partners spread across 6 countries through two projects, suggesting engagement with geographically diverse European research teams. Their network is modest in size but purposefully assembled around diagnostic technology development rather than a single national cluster.

What sets them apart

Microcoat occupies a rare niche as a German SME with hands-on expertise in both the surface chemistry of microcoated biological particles and their application in clinical diagnostics — a combination that is hard to find in a single organization. For a consortium building a point-of-care diagnostic device, they offer a ready-made reagent and assay component capability that most academic partners cannot provide internally. Their focus on complement-system diagnostics is particularly distinctive, as this is a technically demanding area with few specialist suppliers in Europe.

Highlights from their portfolio

• SciFiMed
  This project represents Microcoat's deepest technical engagement, combining multiplex biosensor development, complement factor H diagnostics, and personalized medicine — and runs through 2025, making it their most current and commercially relevant work.
• iLCA
  As Microcoat's first H2020 project and their largest single EC grant (EUR 594,454), iLCA established their European consortium track record in intelligent live cell analysis under the Innovation & SME funding scheme.